Two fetuses can both measure below the 10th percentile at 24 weeks and still diverge: one catches up before birth, the other keeps falling behind and is delivered early. Ultrasound cannot reliably tell them apart at that first diagnosis. Cao and colleagues tried a molecular route, running multi-omics profiling (untargeted LC-MS metabolomics plus data-independent acquisition, or DIA, proteomics) on residual amniotic fluid from clinical amniocentesis to stratify fetal growth re

Of the rheumatoid arthritis (RA) patients who cut their biologic dose in the OPTIBIO trial, 46% flared during up to three years of follow-up, and routine clinical scores gave only a weak hint of who would. A rheumatology and proteomics group in A Coruña, Spain, went back to the trial's banked baseline serum. Label-free mass spectrometry on 44 samples nominated candidates for ELISA in all 194 patients, alongside a 15-plex anti-cytokine autoantibody array. One protein held up.

Most head and neck squamous cell carcinomas (HNSCC) are diagnosed after local spread, and circulating tumor DNA picks up only 20 to 50% of early-stage cases. A blood test that catches Stage I disease would change that math. Writing in eBioMedicine, a Shanghai Jiao Tong University team ran serum metabolomics on 938 people at three hospitals, trained an eight-metabolite classifier on one cohort, and carried it unchanged to two others, one of them measured with a separate isotop

Troponin and NT-proBNP are the blood tests oncologists order when they worry about the heart during anthracycline or trastuzumab treatment. Neither predicts well who will lose pump function. A University of Pennsylvania team, working with Pfizer, tested whether a multi-omics approach could do better in 547 patients with breast cancer. They paired plasma protein profiling of nearly 3,000 targets with rapid LC-MS metabolomics at three timepoints and matched every draw to core-l

Over half of early-stage ovarian cancers present with a normal CA-125, and the marker is weakest where surgeons need it most: separating borderline and low-grade tumors from benign adnexal masses. Rani and colleagues (Journal of Extracellular Vesicles, 2026) tested whether lipidomics could fill that gap. They profiled total plasma and matched small extracellular vesicles (sEVs) from 96 women, including 30 with invasive cancer spread across four histotypes. Key Takeaways Plasm